Hot Products
Industry dynamics
Release time:
2016/11/07 11:14
On the morning of October 24, 2016, the unveiling ceremony of "Jiangsu University Graduate Practice Base" was held in our company. Ouyang Zhen, vice president of the School of Pharmacy of Jiangsu University, Qi Xueyong, director of the Department of Pharmacy, Zhang Caide, chairman of Jiangsu Yongda Pharmaceutical Co., Ltd., Zhang Weijie, general manager, Ge Qing, Minister of Quality Assurance, and Shixiaoya attended the signing and unveiling ceremony.
Guanfu Throw 1.8 billion Enters Pharmaceutical Intermediates Target Funds Hungry for IPO
Release time:
2014/11/20 09:29
On August 17, Guanfu shares issued a reorganization draft after trading suspension for more than three months. It intends to purchase all the shares of Nengte Technology Co., Ltd. (hereinafter referred to as "Nengte Technology") for 1.8 billion yuan by issuing shares to pay cash. Enter the pharmaceutical intermediate industry.
Treatment Technology of Pharmaceutical Intermediates Production Wastewater
Release time:
2014/11/20 09:28
Pharmaceutical intermediate production wastewater is composed of process wastewater and domestic sewage. The comprehensive wastewater quality index is average, and the discharge standard is in accordance with the takeover standard of the local park sewage treatment plant. See Table 1 for wastewater quality and connection standards. The wastewater production is about 260 m3/d, and the design treatment capacity is 300 m3/d.
Release time:
2014/11/20 09:27
As a grand event representing new products and technologies in China's pharmaceutical industry, API China & PHARMPACK & SINOPHEX focuses on improving the overall level of production and research and development of Chinese pharmaceutical raw materials, intermediates, pharmaceutical packaging materials and pharmaceutical equipment enterprises, so as to provide safe and healthy drug use protection for the public. After more than 40 years of development, the exhibition has formed a scale of more than 1000 API manufacturers, more than 300 pharmaceutical packaging companies, more than 200 pharmaceutical equipment companies and more than 30000 professional visitors at home and abroad. This exhibition has set up a "environmental protection & clean exhibition area", inviting excellent environmental protection units at home and abroad to participate.
Huali has developed a number of steroid pharmaceutical intermediates
Release time:
2014/11/20 09:20
Steroidal drugs are the second largest class of drugs after antibiotics. Recently, the research team of Professor Wei Toshiba from the Luhua Institute of Biotechnology of East China University of Science and Technology has made important breakthroughs in the metabolic mechanism of steroid drugs and new production technologies. The team has clarified a number of key mechanisms for the conversion of sterols into useful steroidal drug intermediates for the production of steroidal drugs by mycobacteria, and the application results of the project have applied for a number of patents and are preparing for industrialization.
Release time:
2014/11/20 09:18
Transformation of biological bulk drugs, rapid improvement in profitability: From 2012 to 2014, Jincheng Pharmaceutical's profit contribution business changed from the traditional low-margin cephalosporin intermediate business to the high-margin characteristic bulk drug business. As of the first half of 2014, the company's glutathione net profit ratio has increased from 19% in 2012 to 69%, becoming the company's main profit contribution point at present.
Business Opportunity Information
On the morning of October 24, 2016, the unveiling ceremony of "Jiangsu University Graduate Practice Base" was held in our company. Ouyang Zhen, vice president of the School of Pharmacy of Jiangsu University, Qi Xueyong, director of the Department of Pharmacy, Zhang Caide, chairman of Jiangsu Yongda Pharmaceutical Co., Ltd., Zhang Weijie, general manager, Ge Qing, Minister of Quality Assurance, and Shixiaoya attended the signing and unveiling ceremony.
Guanfu Throw 1.8 billion Enters Pharmaceutical Intermediates Target Funds Hungry for IPO
On August 17, Guanfu shares issued a reorganization draft after trading suspension for more than three months. It intends to purchase all the shares of Nengte Technology Co., Ltd. (hereinafter referred to as "Nengte Technology") for 1.8 billion yuan by issuing shares to pay cash. Enter the pharmaceutical intermediate industry.
Treatment Technology of Pharmaceutical Intermediates Production Wastewater
Pharmaceutical intermediate production wastewater is composed of process wastewater and domestic sewage. The comprehensive wastewater quality index is average, and the discharge standard is in accordance with the takeover standard of the local park sewage treatment plant. See Table 1 for wastewater quality and connection standards. The wastewater production is about 260 m3/d, and the design treatment capacity is 300 m3/d.
As a grand event representing new products and technologies in China's pharmaceutical industry, API China & PHARMPACK & SINOPHEX focuses on improving the overall level of production and research and development of Chinese pharmaceutical raw materials, intermediates, pharmaceutical packaging materials and pharmaceutical equipment enterprises, so as to provide safe and healthy drug use protection for the public. After more than 40 years of development, the exhibition has formed a scale of more than 1000 API manufacturers, more than 300 pharmaceutical packaging companies, more than 200 pharmaceutical equipment companies and more than 30000 professional visitors at home and abroad. This exhibition has set up a "environmental protection & clean exhibition area", inviting excellent environmental protection units at home and abroad to participate.
Huali has developed a number of steroid pharmaceutical intermediates
Steroidal drugs are the second largest class of drugs after antibiotics. Recently, the research team of Professor Wei Toshiba from the Luhua Institute of Biotechnology of East China University of Science and Technology has made important breakthroughs in the metabolic mechanism of steroid drugs and new production technologies. The team has clarified a number of key mechanisms for the conversion of sterols into useful steroidal drug intermediates for the production of steroidal drugs by mycobacteria, and the application results of the project have applied for a number of patents and are preparing for industrialization.
Transformation of biological bulk drugs, rapid improvement in profitability: From 2012 to 2014, Jincheng Pharmaceutical's profit contribution business changed from the traditional low-margin cephalosporin intermediate business to the high-margin characteristic bulk drug business. As of the first half of 2014, the company's glutathione net profit ratio has increased from 19% in 2012 to 69%, becoming the company's main profit contribution point at present.
Contact Information
Address: Room 111 and 113, Building 11, No. 600 Tongjiang Middle Road, Xinbei District, Changzhou City